Brandon Gibson, DO
Internal Medicine · Joplin, MONPI 1891084943
Payments from drug & device makers
Across 247 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$449
- Novo Nordisk$428
- AbbVie$406
- Amgen$384
- Lilly USA, LLC$305
- Pfizer$223
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,03197%
- Education$1243%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $449 |
| Novo Nordisk | 32 | $428 |
| AbbVie(2 entities) | 25 | $406 |
| Amgen | 22 | $384 |
| Lilly USA, LLC | 19 | $305 |
| Pfizer | 13 | $223 |
| GSK | 12 | $182 |
| Astellas Pharma US Inc | 4 | $146 |
| Aroa Biosurgery Incorporated | 2 | $134 |
| Dexcom, Inc. | 7 | $124 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $122 |
| Abbott | 6 | $108 |
| Kowa Pharmaceuticals America, Inc. | 6 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $94 |
| Boehringer Ingelheim | 6 | $89 |
| Merck | 6 | $83 |
| Novartis | 5 | $79 |
| Otsuka America Pharmaceutical, Inc. | 4 | $68 |
| Idorsia Pharmaceuticals US Inc | 4 | $67 |
| Bayer | 4 | $60 |
| Amarin Pharma, Inc. | 4 | $59 |
| Ironwood Pharmaceuticals, Inc | 3 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Eisai Inc. | 2 | $39 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Impel Pharmaceuticals Inc. | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Johnson & Johnson | 1 | $21 |
| Halozyme Inc | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Medtronic | 1 | $12 |
| Fujifilm Sonosite, Inc. | 1 | $12 |
How this compares
$4,155 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 238 | $243,374 |
| FarxigaDapagliflozin Propanediol | 204 | $183,587 |
| EliquisApixaban | 228 | $181,668 |
| JardianceEmpagliflozin | 118 | $103,260 |
| LinzessLinaclotide | 120 | $78,228 |
| MounjaroTirzepatide | 70 | $73,375 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $70,423 |
| TrulicityDulaglutide | 45 | $58,321 |
| JanuviaSitagliptin Phosphate | 67 | $56,471 |
| RexultiBrexpiprazole | 26 | $54,237 |
| MyrbetriqMirabegron | 76 | $53,027 |
| ProliaDenosumab | 26 | $45,179 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 25 | $39,981 |
| XareltoRivaroxaban | 48 | $39,963 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 52 | $38,528 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $428 | $283,355263 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $449 | $232,873302 claims |
| PfizerEliquis, Nurtec Odt | $223 | $194,543240 claims |
| Lilly USA, LLCMounjaro, Trulicity | $305 | $131,696115 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $89 | $123,608139 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Anoro Ellipta | $182 | $122,324219 claims |
| AbbVieLinzess, Vraylar | $406 | $107,553140 claims |
| MerckJanuvia, Janumet Xr | $83 | $69,04392 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $68 | $54,23726 claims |
| Astellas Pharma US IncMyrbetriq | $146 | $53,02776 claims |
| AmgenProlia | $384 | $45,17926 claims |
| Johnson & JohnsonXarelto | $21 | $39,96348 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Joplin
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.